Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333459 · ClinicalTrials.gov registry record · Phase 2
Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT04333459 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 132 participants.
The verdict
NCT04333459, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine. The study is intended to substantiate the Phase 1 results with the 2 mg dose and to also determine if immunogenicity can be retained with a 1 mg dose (for HTNV DNA vaccine).
Interventions
- BIOLOGICAL Hantaan DNA Vaccine/Puumala DNA Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04333459
The ClinicalTrials.gov registry entry for NCT04333459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hantaan DNA Vaccine/Puumala DNA Vaccine is the first listed.
NCT04333459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04333459 about?
NCT04333459 is a clinical study titled "Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS". A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine. The study is intended to substantiate the Phase 1 results with the 2 mg dose and to also determine if immunogeni...
What is the current status of trial NCT04333459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2021-08-23. Estimated completion is 2024-10-15.
What interventions are being tested in trial NCT04333459?
The interventions under investigation include: Hantaan DNA Vaccine/Puumala DNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04333459?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.